Showing 2,121 - 2,140 results of 2,993 for search 'One Day International', query time: 0.10s Refine Results
  1. 2121
  2. 2122
  3. 2123

    Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13]) by A. DeMichele, A. C. Dueck, D. Hlauschek, M. Martin, H. Burstein, G. Pfeiler, N. Zdenkowski, A. Wolff, M. Bellet-Ezquerra, E. Winer, M. Balic, K. Miller, M. Colleoni, D. Lake, G. Rubovsky, D. Cameron, J. Balko, C. F. Singer, Z. Nowecki, H. Iwata, N. Wolmark, K. A. Parraga, H. Rugo, G. G. Steger, T. Traina, G. Werutsky, D. Czajkowska, O. Metzger, S. El-Abed, K. P. Theall, R. D. Lu, P. O’Brien, C. Fesl, E. Mayer, M. Gnant

    Published 2025-01-01
    “…Patients were randomly assigned 1:1 to receive standard adjuvant endocrine therapy (of physicians’ choice) for at least 5 years with or without 2 years of palbociclib, administered orally at a starting dose of 125 mg daily, given for 21 days followed by a 7-day break. …”
    Get full text
    Article
  4. 2124
  5. 2125
  6. 2126
  7. 2127
  8. 2128

    Effectiveness of Glucocorticoids in Acute Respiratory Distress Syndrome: An Umbrella Review by Semagn Mekonnen Abate, Hailemariam Mulugeta Kassim, Bivash Basu, Solomon Nega

    Published 2021-01-01
    “…The umbrella review included nine systematic reviews and meta-analysis and one narrative review with 8491 participants. The methodological quality of the included studies was moderate-to-high quality. …”
    Get full text
    Article
  9. 2129
  10. 2130
  11. 2131

    Etiology of Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP) in Tertiary-Care Hospitals in Thailand: A Multicenter, Retrospective Cohort Study by Rongrungruang Y, Plongla R, Pleumkanitkul S, Hantrakun V, Khawcharoenporn T

    Published 2025-01-01
    “…After diagnosis of NP, 19 patients were transferred to intensive care units with median length of stays of 11 days (IQR 3– 24 days). Fifty-one percent of HAP patients received mechanical ventilation support after the diagnosis of NP with median length of mechanical ventilation use of 12 days (IQR 6– 22 days).Conclusion: A. baumannii, with its significant carbapenem resistance, presents a major HAP/VAP pathogens and imposes a substantial burden on healthcare resources in this study. …”
    Get full text
    Article
  12. 2132

    Interstellar Pickup Ion Observations to 60 au by D. J. McComas, B. L. Shrestha, G. Livadiotis, J. R. Szalay, E. J. Zirnstein, H. A. Elliott, P. C. Brandt, A. R. Poppe, K. N. Singer, A. Stern, A. Verbiscer, the New Horizons Heliophysics Team

    Published 2025-01-01
    “…This study is the first to combine the low time resolution (one day) data inside 49.5 au with the high time resolution (half hour) data outside of that. …”
    Get full text
    Article
  13. 2133
  14. 2134
  15. 2135
  16. 2136

    Therapeutic Effect of Neuromuscular Joint Facilitation on Hemiplegia Patients with Cerebral Infarction by LIN Shaoying, YE Li, CHEN Zhenghong

    Published 2023-08-01
    “…The experimental group received NJF technical training on the basis of the control group, including upper limb extension-adduction-internal rotation mode, upper limb flexion-abduction-external rotation mode, upper limb flexion-adduction-external rotation mode and upper limb extension-abduction-internal rotation mode, 60 minutes a time, of which NJF technical training lasted for 20 minutes, the treatment content in the control group was shortened to 40 minutes a time, once a day, five days a week, continuous training for 10 days. …”
    Get full text
    Article
  17. 2137

    Protocol, rationale and design of DAbigatran for Stroke PreVention In Atrial Fibrillation in MoDerate or Severe Mitral Stenosis (DAVID-MS): a randomised, open-label study by Andrew Ng, Esther W Chan, Duo Huang, Cheung Chi Lam, Ning Tan, Chung Wah Siu, Jo Jo Hai, Ji-yan Chen, Chun Ka Wong, Mi Zhou, Yuk Ming LAU, Chor Cheung Frankie Tam, Yiu Tung Anthony Wong, See Yue Arthur Yung, Ki Wan Kelvin Chan, Yingqing Feng, Chi Yui Yung, Kwok Lun Lee, Chun Wai Choi, Ho Lam, Katherine Fan, Man Hong Jim, Kai Hang Yiu, Bryan P. Yan

    Published 2020-09-01
    “…Patients with AF aged ≥18 years with moderate or severe MS not planned for valvular intervention in the coming 12 months will be randomised in a 1:1 ratio to receive dabigatran 110 mg or 150 mg two times per day or warfarin with international normalised ratio 2–3 in an open-label design. …”
    Get full text
    Article
  18. 2138
  19. 2139
  20. 2140